>>Analytical Standards>>Paclitaxel-d5

Paclitaxel-d5

Catalog No.GC47853

Paclitaxel-d5는 중수소 표지된 Paclitaxel입니다. 파클리탁셀은 자연적으로 발생하는 항종양제이며 튜불린 중합을 안정화합니다.

Products are for research use only. Not for human use. We do not sell to patients.

Paclitaxel-d5 Chemical Structure

Cas No.: 1129540-33-5

Size 가격 재고 수량
1 mg
US$643.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Paclitaxel-d5 contains five deuterium atoms. It is intended for use as an internal standard for the quantification of paclitaxel using GC- or LC-MS. Paclitaxel is cytotoxic against a variety of cancer cell lines with IC50 values ranging from 2.5-7.5 nM.1 It disrupts multipolar spindle formation, inducing cell cycle arrest in various human cell cancer lines (IC50s = 6.7-18.5 nM) at both prophase and G1.2 It also initiates apoptosis of cancer cells through multiple mechanisms involving p53-dependent and -independent pathways, Bcl-2 family members, cyclin-dependent kinases, and c-Jun N-terminal kinases/stress-activated protein kinases.3

1.Liebmann, J.E., Cook, J.A., Lipschultz, C., et al.Cytotoxic studies of paclitaxel (Taxol) in human tumour cell linesBr. J. Cancer68(6)1104-1109(1993) 2.Woods, C.M., Zhu, J., McQueney, P.A., et al.Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathwayMol. Med.1(5)506-526(1995) 3.Wang, T.h., Wang, H.S., and Soong, Y.K.Paclitaxel-induced cell death: Where the cell cycle and apoptosis come togetherCancer88(11)2619-2628(2000)

리뷰

Review for Paclitaxel-d5

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Paclitaxel-d5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.